作者：高福等
发表年份：2020年
发表期刊：Cell
作者单位：中国科学院北京生命科学研究院等
地区：北京市
文章摘要
Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.
实验方法
使用机型：Biacore 8K
实验类型：亲和力/动力学表征
样品类型：配体：RBD-dimer and -monomer 蛋白；分析物：Fabs
实验芯片：S系列CM5芯片
配体固定方式：氨基偶联
运行缓冲液：PBST (10mM Na2HPO4; 2mM KH2PO4, pH 7.4; 137mM NaCl; 2.7mM KCl; 0.005% Tween 20)
再生条件：10 mM NaOH
产品信息
| 类别 | 货号 | 产品名称 | 规格 |
|---|---|---|---|
| 主机 | 29722782 | Biacore 8K System | |
| 芯片 | 29104988 | S系列CM5芯片 | 1片 |
| 芯片 | BR100530 | S系列CM5芯片 | 3片 |
| 芯片 | 29149603 | S系列CM5芯片 | 10片 |
| 试剂盒 | BR100050 | 氨基偶联试剂盒 | |
| 运行缓冲液 | 28995084 | PBS-P+ (10×) | 1 × 1000 mL |
| 试剂 | BR100358 | 50mM 氢氧化钠 | 1 × 100 mL |
Reference
Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022 Jun 23;185(13):2265-2278.e14. doi: 10.1016/j.cell.2022.04.029. Epub 2022 Apr 27. PMID: 35568034; PMCID: PMC9042943.